{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:05:50Z","timestamp":1744344350206,"version":"3.40.4"},"reference-count":60,"publisher":"ARAN Ediciones","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutr Hosp"],"published-print":{"date-parts":[[2025]]},"DOI":"10.20960\/nh.05562","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T09:56:17Z","timestamp":1744278977000},"source":"Crossref","is-referenced-by-count":0,"title":["Integrase strand transfer inhibitors, their impact in adipose tissue and weight gain in people living with HIV - A narrative review"],"prefix":"10.20960","author":[{"given":"Ericka Nelly","family":"Pompa-Mera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Magdalena","family":"Valle-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elba","family":"Reyes-Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Mata Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireya","family":"N\u00fa\u00f1ez Armend\u00e1riz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Gayt\u00e1n-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8588","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00249-1"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10040909"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/v13020205"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40506-019-00203-7"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/v14122591"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00898-8"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00063"},{"key":"ref8","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2023. Avalaible from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf [Accessed on August 11, 2024]."},{"key":"ref9","unstructured":"EACS Guidelines V12.0 2024. Available in: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/ [Accessed on August 11, 2024]."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200301010-00007"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1644317"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Beltr\u00e1n LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, Garc\u00eda-Puig J, Moreno JA. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc Health Risk Manag. 2015; 11:35-48.","DOI":"10.2147\/VHRM.S65885"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000181011.62385.91"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f33557"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328333ea9e"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22742"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30016-4"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa177"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw017"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy201"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001675"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904340"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001525"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30241-1"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25484"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2021.100173"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Bakal DR, Coelho LE, Luz PM, Clark JL, De Boni RB, Cardoso SW, et al. Obesity following ART initiation is common and influenced by both traditional and HIV-\/ART-specific risk factors. J Antimicrob Chemother. 2018; 73(8):2177-2185.","DOI":"10.1093\/jac\/dky145"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, et al. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2021; 73(2):e485-e493.","DOI":"10.1093\/cid\/ciaa988"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Schafer JJ, Sassa KN, O'Connor JR, Shimada A, Keith SW, DeSimone JA. Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide. Open Forum Infect Dis. 2019; 6(10): ofz414.","DOI":"10.1093\/ofid\/ofz414"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Kauppinen KJ, Aho I, Sutinen J. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain. AIDS. 2022; 36(10):1337-1344.","DOI":"10.1097\/QAD.0000000000003245"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Verburgh ML, Wit FWNM, Boyd A, Reiss P, Van der Valk M; ATHENA national observational cohort. No evidence of rapid reversibility of tenofovir alafenamide and\/or integrase strand transfer inhibitor-associated weight gain. AIDS. 2023 Oct 1;37(12):1843-1850.","DOI":"10.1097\/QAD.0000000000003654"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Wohl DA, Koethe JR, Sax PE, McComsey GA, Kuritzkes DR, Moyle G, et al. Antiretrovirals and Weight Change: Weighing the Evidence. Clin Infect Dis. 2024; 12:ciae191.","DOI":"10.1093\/cid\/ciae191"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis. 2006; 42(6):836-42.","DOI":"10.1086\/500398"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Tate T, Willig AL, Willig JH, Raper JL, Moneyham L, Kempf MC, et al. HIV infection and obesity: where did all the wasting go? Antivir Ther. 2012; 17(7):1281-9.","DOI":"10.3851\/IMP2348"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Kumar S, Samaras K. The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Front Endocrinol (Lausanne). 2018; 9:705.","DOI":"10.3389\/fendo.2018.00705"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Otake K, Omoto S, Yamamoto T, Okuyama H, Okada H, Okada N,et al. HIV-1 Nef protein in the nucleus influences adipogenesis as well as viral transcription through the peroxisome proliferator-activated receptors. AIDS. 2004; 18(2):189-98.","DOI":"10.1097\/00002030-200401230-00007"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Agarwal N, Iyer D, Patel SG, Sekhar RV, Phillips TM, Schubert U, et al. HIV-1 Vpr induces adipose dysfunction in vivo through reciprocal effects on PPAR\/GR co-regulation. Sci Transl Med. 2013; 5(213):213ra164.","DOI":"10.1126\/scitranslmed.3007148"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Matute P, P\u00e9rez-Mart\u00ednez L, Blanco JR, Oteo JA. Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. Oxid Med Cell Longev. 2013; 2013:493413.","DOI":"10.1155\/2013\/493413"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Gorwood J, Ejlalmanesh T, Bourgeois C, Mantecon M, Rose C, Atlan M,et al. SIV Infection and the HIV Proteins Tat and Nef Induce Senescence in Adipose Tissue and Human Adipose Stem Cells, Resulting in Adipocyte Dysfunction. Cells. 2020a; 9(4):854.","DOI":"10.3390\/cells9040854"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Bailin SS, Gabriel CL, Fan R, Ye F, Nair S, Terry JG, et al. Relationship of Subcutaneous Adipose Tissue Inflammation-Related Gene Expression With Ectopic Lipid Deposition in Persons With HIV. J Acquir Immune Defic Syndr. 2022; 90(2):175-183.","DOI":"10.1097\/QAI.0000000000002926"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Gorwood J, Bourgeois C, Pourcher V, Pourcher G, Charlotte F, Mantecon M, et al. The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human\/Simian Adipose Tissue and Human Adipocytes. Clin Infect Dis. 2020b; 71(10):e549-e560.","DOI":"10.1093\/cid\/ciaa259"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Ghaben AL, Scherer PE. Adipogenesis and metabolic health. Nat Rev Mol Cell Biol. 2019; 20(4):242-258.","DOI":"10.1038\/s41580-018-0093-z"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and Weight Gain in Persons with HIV. Curr HIV\/AIDS Rep. 2020; 17(2):138-150.","DOI":"10.1007\/s11904-020-00483-5"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Ngono Ayissi K, Gorwood J, Le Pelletier L, Bourgeois C, Beaup\u00e8re C, Auclair M, et al. Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes. Cells. 2022; 11(11):1841.","DOI":"10.3390\/cells11111841"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Ahmed B, Farb MG, Gokce N. Cardiometabolic implications of adipose tissue aging. Obes Rev. 2024; 30:e13806.","DOI":"10.1111\/obr.13806"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Zhao H, Goetz MB. Complications of HIV infection in an ageing population: challenges in managing older patients on long-term combination antiretroviral therapy. J Antimicrob Chemother. 2011; 66(6):1210-4.","DOI":"10.1093\/jac\/dkr058"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and Weight Gain in Persons with HIV. Curr HIV\/AIDS Rep. 2020; 17(2):138-150.","DOI":"10.1007\/s11904-020-00483-5"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Kim DJ, Westfall AO, Chamot E, Willig AL, Mugavero MJ, Ritchie C, et al. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr. 2012; 61(5):600\u20135. 9.","DOI":"10.1097\/QAI.0b013e31827303d5"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Sattler FR, He J, Letendre S, Wilson C, Sanders C, Heaton R, et al. Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation. J Acquir Immune Defic Syndr. 2015; 68(3):281\u20138.","DOI":"10.1097\/QAI.0000000000000458"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Milic J, Calza S, Cantergiani S, Albertini M, Gallerani A, Menozzi M, et al. Sarcopenic Obesity Phenotypes in Patients With HIV: Implications for Cardiovascular Prevention and Rehabilitation. Can J Cardiol. 2023; 39(11S): S359-S367.","DOI":"10.1016\/j.cjca.2023.08.027"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Capeau J, Lagathu C, Ngono Ayissi K, F\u00e8ve B, B\u00e9r\u00e9ziat V. HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals. Ann Endocrinol (Paris). 2024; 85(3):255-258.","DOI":"10.1016\/j.ando.2024.05.005"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Patel YS, Doshi AD, Levesque AE, Lindor S, Moranville RD, Okere SC, et al. Weight Gain in People with HIV: The Role of Demographics, Antiretroviral Therapy, and Lifestyle Factors on Weight. AIDS Res Hum Retroviruses. 2023; 39(12):652-661.","DOI":"10.1089\/aid.2023.0008"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Toribio M, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024; 38(12):1758-1764.","DOI":"10.1097\/QAD.0000000000003965"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014; 312(4):380-9.","DOI":"10.1001\/jama.2014.8334"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Eckard AR, Wu Q, Sattar A, Ansari-Gilani K, Labbato D, Foster T, et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. Lancet Diabetes Endocrinol. 2024; 12(8):523-534.","DOI":"10.1016\/S2213-8587(24)00150-5"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021; 385(6):503-515.","DOI":"10.1056\/NEJMoa2107519"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, Wu Q, Du Y, Gurbuz S, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023; 389(6):514-526.","DOI":"10.1056\/NEJMoa2301972"},{"key":"ref59","unstructured":"UNAIDS. Understanding measures of progress towards the 95\u201395\u201395 HIV testing, treatment and viral suppression targets. 2024. Updated March 11, 2024. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/progress-towards-95-95-95_es.pdf [Accessed on August 11, 2024]."},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Bavaro DF, Laghetti P, Poliseno M, De Gennaro N, Di Gennaro F, Saracino A. A Step Closer to the \"Fourth 90\": A Practical Narrative Review of Diagnosis and Management of Nutritional Issues of People Living with HIV. Diagnostics (Basel). 2021; 11(11):2047.","DOI":"10.3390\/diagnostics11112047"}],"container-title":["Nutrici\u00f3n Hospitalaria"],"original-title":[],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T09:56:30Z","timestamp":1744278990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nutricionhospitalaria.org\/articles\/05562\/show"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":60,"URL":"https:\/\/doi.org\/10.20960\/nh.05562","relation":{},"ISSN":["1699-5198","0212-1611"],"issn-type":[{"value":"1699-5198","type":"electronic"},{"value":"0212-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}